Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors.

Cell - 20 Sept 2018

Huang Xun, Yan Juan, Zhang Min, Wang Yafang, Chen Yi, Fu Xuhong, Wei Rongrui, Zheng Xing-Ling, Liu Zhiwei, Zhang Xiong, Yang Hong, Hao Bingbing, Shen Yan-Yan, Su Yi, Cong Xiaoji, Huang Min, Tan Minjia, Ding Jian, Geng Meiyu

Abstract excerpt

Mutations or aberrant upregulation of EZH2 occur frequently in human cancers, yet clinical benefits of EZH2 inhibitor (EZH2i) remain unsatisfactory and limited to certain hematological malignancies. We profile global posttranslational histone modification changes across a large panel of cancer cell lines with various sensitivities to EZH2i. We report here oncogenic transcriptional reprogramming mediated by MLL1's...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enhancer of Zeste Homolog 2 Protein
Share to Epigenomics

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Histone Code

Share to Histone-Lysine N-Methyltransferase

Share to Mice, SCID

Share to Myeloid-Lymphoid Leukemia Protein

Share to p300-CBP Transcription Factors

Share to Polycomb Repressive Complex 2

Source

Identifiers

PMID: 30220457
DOI: 10.1016/j.cell.2018.08.058

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors.PMID 30220457Read ↗

AEBP2-Directed H3K27me2 Defines a Specific Vulnerability in EZH2-mutant LymphomaSemantic proximity Read ↗

EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.Semantic proximity Read ↗

Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2.Semantic proximity Read ↗

Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effectsSemantic proximity Read ↗

Targeting EZH2 in cancer.Semantic proximity Read ↗

EZH2: an epigenetic gatekeeper promoting lymphomagenesis.Semantic proximity Read ↗

The biology of novel dual histone methyltransferase inhibitorsSemantic proximity Read ↗

EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.Semantic proximity Read ↗

<i>EZH2</i> mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibitionSemantic proximity Read ↗

Somatic alterations and dysregulation of epigenetic modifiers in cancers.Semantic proximity Read ↗

EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphomaSemantic proximity Read ↗

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.